Theriva™ Biologics Announces Positive Outcomes From the Second Meeting of the Independent Data Monitoring Committee for Virage, the Company’s Phase 2B Clinical Trial of Vcn-01 in Combination With Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma (Pdac)

THOMSON REUTERS
31 Mar

Theriva™ Biologics Announces Positive Outcomes From the Second Meeting of the Independent Data Monitoring Committee for Virage, the Company’s Phase 2B Clinical Trial of Vcn-01 in Combination With Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma (Pdac)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10